Bruker Corp
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 4 days.
- Recent price momentum is +11.8% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 7.4% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation D+
How expensive the stock is versus earnings, sales and its own 5-year history.
| Forward P/E | 57.9x | Better than 6% |
| Price / Sales | 2.7x | Better than 47% |
Growth D+
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 10.7% | Better than 66% |
| Net income CAGR (3Y) | -25.8% | Better than 13% |
| Free cash flow CAGR (3Y) | -54.3% | Better than 3% |
Profitability C
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 45.9% | Better than 57% |
| Operating margin | 6.9% | Better than 41% |
| Net margin | -0.7% | Better than 25% |
| Return on equity | -1.1% | Better than 27% |
| Return on invested capital | 0.3% | Better than 29% |
Momentum B+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -5.1% | Better than 62% |
| 6-month return | 23.8% | Better than 86% |
| 12-month return (ex latest month) | 22.3% | Better than 62% |
| Distance below 52-week high | 18.2% | Better than 65% |
Financial Health C
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.7x | Better than 48% |
| Debt to assets | 32.7% | Better than 37% |
| Interest coverage | 1.4x | Better than 31% |
| Free cash flow / net income | 120.2% | Better than 52% |
Analyst View C-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 42.9% | Better than 23% |
| Upside to average target | 18.4% | Better than 30% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 62.10
- Open
- 60.65
- Day range
- 56.13 - 61.10
- Avg price
- 57.60
- Volume
- 2.25M
- Turnover
- 129.64M
- Turnover ratei
- 2.16%
- Volume ratioi
- 1.11
- Amplitudei
- 8.00%
- 52-week rangei
- 32.26 - 68.98
Valuation
- P/Ei
- -376.40
- P/E (TTM)i
- -51.33
- P/Bi
- 3.77
- EPSi
- -0.15
- Book value / shi
- 14.97
- Net profit
- -22.91M
- Net assets
- 2.29B
Share structure
- Market cap
- 8.62B
- Float capi
- 5.88B
- Shares out
- 152.72M
- Float sharesi
- 104.08M
Dividend & listing
- Div yield (TTM)i
- 0.35%
- Dividend (TTM)
- 0.20
- Listing date
- 1970-01-01
18.2% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-136.14M net over the window
Short interest
- Shares short
- 11.25M
- % of floati
- 7.38%
- Days to coveri
- 5.43
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Bruker Corp (BRKR)?
Bruker Corp last traded at 56.46. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Bruker Corp's market cap?
About 8.62B.
What is the P/E ratio of Bruker Corp?
The trailing twelve-month P/E is -51.33. The Valuation tab shows it against the stock's own five-year range.
Does Bruker Corp pay a dividend?
Yes. The trailing dividend yield is 0.35%. The 2025 payout was little changed from 2024. See the Dividends tab for the full payment history.
Is Bruker Corp a buy according to analysts?
The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 66.86, which implies 18.4% upside from the current price. This is not investment advice.
What is Bruker Corp's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Bruker Corp a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:02:27 · For reference only, not investment advice and not tailored to your situation.
Bruker Corp discussion 0 comments